Literature DB >> 30093456

Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.

Malte Lenders1, Eva Brand2.   

Abstract

Entities:  

Keywords:  Fabry disease; antibodies; immunosuppression; infusion associated reactions; treatment

Mesh：

Substances：

Year:  2018        PMID： 30093456      PMCID： PMC6115664          DOI： 10.1681/ASN.2018030329

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  123 in total

1.  Nicotiana benthamiana α-galactosidase A1.1 can functionally complement human α-galactosidase A deficiency associated with Fabry disease.

Authors:  Kassiani Kytidou; Jules Beekwilder; Marta Artola; Eline van Meel; Ruud H P Wilbers; Geri F Moolenaar; Nora Goosen; Maria J Ferraz; Rebecca Katzy; Patrick Voskamp; Bogdan I Florea; Cornelis H Hokke; Herman S Overkleeft; Arjen Schots; Dirk Bosch; Navraj Pannu; Johannes M F G Aerts
Journal:  J Biol Chem       Date:  2018-04-19       Impact factor: 5.157

2.  Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.

Authors:  William R Wilcox; Gabor E Linthorst; Dominique P Germain; Ulla Feldt-Rasmussen; Stephen Waldek; Susan M Richards; Dana Beitner-Johnson; Marta Cizmarik; J Alexander Cole; Wytske Kingma; David G Warnock
Journal:  Mol Genet Metab       Date:  2011-12-14       Impact factor: 4.797

3.  High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.

Authors:  Juna M de Vries; Nadine A M E van der Beek; Marian A Kroos; Lale Ozkan; Pieter A van Doorn; Susan M Richards; Crystal C C Sung; Jan-Dietert C Brugma; Adrienne A M Zandbergen; Ans T van der Ploeg; Arnold J J Reuser
Journal:  Mol Genet Metab       Date:  2010-08-14       Impact factor: 4.797

4.  Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Authors:  A Mehta; M Beck; P Elliott; R Giugliani; A Linhart; G Sunder-Plassmann; R Schiffmann; F Barbey; M Ries; J T R Clarke
Journal:  Lancet       Date:  2009-12-12       Impact factor: 79.321

5.  Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.

Authors:  Dominique P Germain; Derralynn A Hughes; Kathleen Nicholls; Daniel G Bichet; Roberto Giugliani; William R Wilcox; Claudio Feliciani; Suma P Shankar; Fatih Ezgu; Hernan Amartino; Drago Bratkovic; Ulla Feldt-Rasmussen; Khan Nedd; Usama Sharaf El Din; Charles M Lourenco; Maryam Banikazemi; Joel Charrow; Majed Dasouki; David Finegold; Pilar Giraldo; Ozlem Goker-Alpan; Nicola Longo; C Ronald Scott; Roser Torra; Ahmad Tuffaha; Ana Jovanovic; Stephen Waldek; Seymour Packman; Elizabeth Ludington; Christopher Viereck; John Kirk; Julie Yu; Elfrida R Benjamin; Franklin Johnson; David J Lockhart; Nina Skuban; Jeff Castelli; Jay Barth; Carrolee Barlow; Raphael Schiffmann
Journal:  N Engl J Med       Date:  2016-08-11       Impact factor: 91.245

6.  Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.

Authors:  F Baehner; C Kampmann; C Whybra; E Miebach; C M Wiethoff; M Beck
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

7.  Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.

Authors:  Frank Weidemann; Markus Niemann; Frank Breunig; Sebastian Herrmann; Meinrad Beer; Stefan Störk; Wolfram Voelker; Georg Ertl; Christoph Wanner; Jörg Strotmann
Journal:  Circulation       Date:  2009-01-19       Impact factor: 29.690

8.  Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.

Authors:  Dominique P Germain; Joel Charrow; Robert J Desnick; Nathalie Guffon; Judy Kempf; Robin H Lachmann; Roberta Lemay; Gabor E Linthorst; Seymour Packman; C Ronald Scott; Stephen Waldek; David G Warnock; Neal J Weinreb; William R Wilcox
Journal:  J Med Genet       Date:  2015-03-20       Impact factor: 6.318

9.  Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.

Authors:  Derralynn A Hughes; Kathleen Nicholls; Suma P Shankar; Gere Sunder-Plassmann; David Koeller; Khan Nedd; Gerard Vockley; Takashi Hamazaki; Robin Lachmann; Toya Ohashi; Iacopo Olivotto; Norio Sakai; Patrick Deegan; David Dimmock; François Eyskens; Dominique P Germain; Ozlem Goker-Alpan; Eric Hachulla; Ana Jovanovic; Charles M Lourenco; Ichiei Narita; Mark Thomas; William R Wilcox; Daniel G Bichet; Raphael Schiffmann; Elizabeth Ludington; Christopher Viereck; John Kirk; Julie Yu; Franklin Johnson; Pol Boudes; Elfrida R Benjamin; David J Lockhart; Carrolee Barlow; Nina Skuban; Jeffrey P Castelli; Jay Barth; Ulla Feldt-Rasmussen
Journal:  J Med Genet       Date:  2016-11-10       Impact factor: 6.318

10.  Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme.

Authors:  David Bodensteiner; C Ronald Scott; Katherine B Sims; Gillian M Shepherd; Rebecca D Cintron; Dominique P Germain
Journal:  Genet Med       Date:  2008-05       Impact factor: 8.822
View more
  17 in total

Review 1.  Fabry disease: what the cardiologist should consider in non-cardiac screening, diagnosis, and management-narrative review.

Authors:  Claudia Regenbogen; Matthias Christoph Braunisch; Christoph Schmaderer; Uwe Heemann
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

Review 2.  Narrative review on Morbus Fabry: diagnosis and management of cardiac manifestations.

Authors:  Aleš Linhart; Tomáš Paleček
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

Review 3.  Fabry disease-what cardiologists can learn from the nephrologist: a narrative review.

Authors:  Christine E Kurschat
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

4.  Protection is not always a good thing: The immune system's impact on gene therapy.

Authors:  Martiela Vaz de Freitas; Lariane Frâncio; Laura Haleva; Ursula da Silveira Matte
Journal:  Genet Mol Biol       Date:  2022-07-15       Impact factor: 2.087

Review 5.  New drugs for the treatment of Anderson-Fabry disease.

Authors:  Sandro Feriozzi; Derralynn A Hughes
Journal:  J Nephrol       Date:  2020-03-20       Impact factor: 3.902

Review 6.  Fabry Disease: The Current Treatment Landscape.

Authors:  Malte Lenders; Eva Brand
Journal:  Drugs       Date:  2021-03-15       Impact factor: 9.546

7.  Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol.

Authors:  Eleonora Riccio; Mario Zanfardino; Monica Franzese; Ivana Capuano; Pasquale Buonanno; Lucia Ferreri; Maria Amicone; Antonio Pisani
Journal:  Mol Genet Genomic Med       Date:  2021-03-23       Impact factor: 2.183

Review 8.  Fabry disease and kidney involvement: starting from childhood to understand the future.

Authors:  Roberto Chimenz; Valeria Chirico; Caterina Cuppari; Giorgia Ceravolo; Daniela Concolino; Paolo Monardo; Antonio Lacquaniti
Journal:  Pediatr Nephrol       Date:  2021-04-30       Impact factor: 3.651

9.  Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres.

Authors:  Aizeddin A Mhanni; Christiane Auray-Blais; Michel Boutin; Alie Johnston; Kaye LeMoine; Jill Patterson; Johannes M F G Aerts; Michael L West; Cheryl Rockman-Greenberg
Journal:  Mol Genet Metab Rep       Date:  2020-06-24

Review 10.  The Cardiovascular Phenotype in Fabry Disease: New Findings in the Research Field.

Authors:  Daniela Sorriento; Guido Iaccarino
Journal:  Int J Mol Sci       Date:  2021-01-29       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.